Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents
12/05/2008 15:19
PR Newswire
TEL AVIV, Israel, May 12 /PRNewswire/ --
- Provides the Optimal Combination of Scaffolding, Deliverability and
Conformability
Medinol is proud to announce that it has received CE Mark for its
Presillion(TM) CoCr Coronary Stent, enabling physicians to treat coronary
artery lesions with a technologically innovative flexible closed cell design
stent.
Presillion(TM) preserves the superb scaffolding the unprecedented balance
of flexibility and conformability identified with the NIRflex flexible closed
cell design. The unique geometry of the Presillion(TM) complies with the long
term needs of patients for both safety and efficacy in addition to ease of
delivery for the physicians. The alternating rings provide simultaneously
optimal flexibility and enhanced scaffolding. Dr. Kobi Richter, chairman of
the board and chief technology officer of Medinol says, "Cobalt Chromium
enables us to reduce the strut thickness and overall cell size by up to 25%
compared to stainless steel while retaining superior scaffolding through the
unique flexible closed cell design; this material also maintains a much
higher fatigue resistance and radiopacity than the common stainless steel
stents."
"Medinol is proud to introduce a new family of stent systems to the
market, the first of which is the Presillion(TM). By utilizing its expertise
and IP Medinol is proving itself once again as a leading developer, designer
and manufacturer of stents and stent systems," says Dr. Judith Richter, chief
executive officer for Medinol.
Medinol partnered with Cordis, a Johnson and Johnson company, last year,
and will be distributing the Presillion globally. "We are happy that we are
able to enrich Cordis's Cath Lab Cubed offer to market," says Dr. Richter.
Recent research recognized the value of Bare Metal Stents and the growing
versatility of treatments of complex coronary artery disease. The
introduction of the Presillion enhances the physicians' ability to choose the
most suitable stent for each patient and the long term benefits provided for
each individual vessel and lesion.
The Presillion comes in diameters ranging from 2.5-4.0 mm. and in lengths
ranging from 8-32 mm. The Presillion stent system and can be used to treat
various lesion types: de novo, restenotic lesions, total occlusions,
bifurcations, and acute myocardial infarction.
Medinol continues setting new standards in the stenting industry through
design innovation and advance technology manufacturing methods. Medinol is
constantly enhancing its technology and producing stenting solutions for:
coronary and vascular systems, bifurcation stenting and biliary stenting.
Medinol is currently developing advanced technology stents and additional
therapeutic solutions for the treatment of vascular disease that will be
introduced to the market in the near future.
Contact:
Tamar Hadar
Senior Director, Global Sales & Marketing
Medinol Ltd.
Office: +972-3-7679000 ext. 256
Tamar.Hadar@MEDINOL.COM
Contact: Tamar Hadar, Senior Director, Global Sales & Marketing, Medinol Ltd. Office: +972-3-7679000 ext. 256, Tamar.Hadar@MEDINOL.COM